ACE and chronic kidney disease: While the CREDENCE trial had enrolled patients with chronic kidney disease and was required to be on ACE/ARB (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker) inhibitor therapy, the DAPA-HF trial enrolled patients with diagnosed heart failure on established therapy and a medical device.